Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Wave comparisons of clinical characteristics and outcomes of COVID-19 admissions - Exploring the impact of treatment and strain dynamics

Anna Freeman a,b,1, Alastair Watson a,b,1, Paul O’Regan c,1, Oskar Wysocki c,d,1, Hannah Burke a,b, Andre Freitas c,d,h, Robert Livingstone a,b, Ahilanadan Dushianthan a,b,g, Michael Celinski a,b, James Batchelor a,b,6,f, Hang Phan a,f,g, Florina Borca a,b,6,8, Paul Fitzpatrick c, Donal Landers c, Tom MA Wilkinson a,b,1

a Faculty of Medicine, University of Southampton, United Kingdom
b University Hospitals Southampton NHS Foundation Trust, United Kingdom
c Digital Experimental Cancer Medicine Team, Cancer Biomarker Centre, Cancer Research UK Manchester Institute, The University of Manchester, United Kingdom
d Department of Computer Science, The University of Manchester, United Kingdom
e Institute for Life Sciences, University of Southampton, United Kingdom
f Institute for Life Sciences, University of Southampton, United Kingdom
1 Clinical Informatics Research Unit Faculty of Medicine, University of Southampton, United Kingdom
3 NIHR Southampton Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, United Kingdom
8 Idiap Research Institute, Switzerland

ABSTRACT

Objectives: Dexamethasone has now been incorporated into the standard of care for COVID-19 hospital patients. However, larger intensive care unit studies have failed to show discernible improvements in mortality in the recent wave. We aimed to investigate the impacts of these factors on disease outcomes in a UK hospital study.

Methods: This retrospective observational study reports patient characteristics, interventions and outcomes in COVID-19 patients from a UK teaching hospital; cohort 1, pre 16th June-2020 (pre-dexamethasone); cohort 2, 17th June to 30th November-2020 (post-dexamethasone, pre-VOC 202,012/01 as dominant strain); cohort 3, 1st December-2020 to 3rd March-2021 (during establishment of VOC202012/01 as the dominant strain).

Results: Dexamethasone treatment was more common in cohorts 2 and 3 (42.7% and 51.6%) compared with cohort 1 (25.5%). After adjusting for risk, odds of death within 28 days were 2-fold lower in cohort 2 vs 1 (OR:0.86,[0.64, 1.15],p = 0.006). Mortality was higher cohort 3 vs 2 (20% vs 14%); but not significantly different to cohort 1 (OR: 0.86,[0.64, 1.15],p = 0.308).

Conclusions: The real world finding of lower mortality following dexamethasone supports the published trial evidence and highlights ongoing need for research with introduction of new treatments and ongoing concern over new COVID-19 variants.

1. Introduction

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection leads to a range of clinical outcomes from asymptomatic carriage to severe Coronavirus disease (COVID-19) [1,2,23,30]. During the first COVID-19 peak, May-2020, large clinical trials, including ACCORD and RECOVERY, were initiated to rapidly test and identify new trial identified dexamethasone as effective at reducing deaths in patients receiving oxygen or invasive ventilation by a third, and was rapidly translated into standard of care for all COVID-19 patients with oxygen requirement [4, 6, 7]. However, since then, the larger intensive care unit studies, such as the Intensive Care National Audit and Research Centre (ICNARC) report on COVID-19 in critical care, have failed to show discernible improvements in oxygen requirements and 28-day in-hospital mortality risk in the recent wave [8].

A new SARS-CoV-2 virus lineage (B.1.1.7), known as Variant of Concern (VOC)202,012/01, the “Kent” variant, was detected in England...
in September-2020 and reported to have increased transmissibility [9]. A recent report highlighted infection with this lineage to associate with increased oxygen requirements and a 60% higher 28-day in-hospital mortality risk in intensive care unit (ITU) patients [10]. By the peak of the third wave (end of December-2020), this new variant established itself as the most prevalent SARS-CoV-2 lineage in South East of England (Fig. 1) [11].

Using data from the Research Evaluation Alongside Clinical Treatment in COVID-19 (REACT COVID-19) study, established to provide a real-time database of a broader cohort of well-characterised hospital patients with COVID-19 [12, 13], we report COVID-19 patient clinical and biochemical parameters, interventions and outcomes for each COVID-19 wave. Through comparison of the pre-dexamethasone first wave (cohort 1), the pre-VOC202012/01 post dexamethasone period (cohort 2) and the most recent VOC202012/01 wave (cohort 3), we aimed to gain insights around the impact of changing clinical practice and dexamethasone use and VOC202012/01 on clinical outcomes.

2. Methods

2.1. Study design and setting

Data were collected as part of the REACT observational and bio-banking study of COVID-19 on COVID-19 positive patients admitted to University Hospital Southampton 7th March-2020–3rd March-2021 [12]. Ethical approval was obtained from HRA specific review board (REC 20/HRA/2986).

2.2. Participants

Patients were included in the study if admitted to hospital with a positive RT-PCR result from nasopharyngeal swab or bronchoalveolar lavage for SARS-CoV-2 and were split into 3 cohorts dependant on date of presentation (Table 1). Patients with a first positive test date fewer than 28 days before the data cut-off date were excluded.

2.3. Variables

Patients’ characteristics included demographics (age, sex and body mass index) and comorbidities (including asthma, COPD, cardiac disease and others). Patients defined as having a neurological disease included those recorded as having a diagnosis of epilepsy, a demyelinating condition (e.g. multiple sclerosis), an extra-pyramidal condition (e.g. Parkinson’s disease), stroke, myasthenia gravis, Huntington’s, spina bifida, motor neuron disease, cerebral palsy, a degenerative disease of the nervous system, spinal muscular atrophy, hydrocephalus, alcohol related neurological disease, vascular related neurological disease or Alzheimer’s.

Data collected at admission and throughout hospitalization as part of routine clinical care were recorded (Table 3). Timing, dose and duration of treatments, including corticosteroids, anticoagulants, antibiotics, antivirals and antifungals were collected. Data up to and including 28 days after each patient’s first positive test were included in the analysis.

2.4. Outcomes

The primary outcome was in-hospital mortality within 28 days of first positive test. For evaluation of changes in parameters, analysis was restricted to patients who were hospitalised for 2 or more days.

2.5. Data sources / measurements

Clinical data were captured longitudinally, with change over time treated as explicit. A detailed study protocol and overview of methodology has previously been published [12].

In order to adjust the analysis of mortality based on known COVID-19 risk factors, weighted risk scores were calculated for patients after the first positive SARS-CoV-2 test (first available value up to and including the day after test) using available variables and equivalent weightings as described previously for 4C mortality score. Briefly, the following weightings were applied: age (50–60 years score +2, 60–70 years score +4, 70–80 years score +6, >80 years score +7); sex (male score +1); number of relevant comorbidities (1 score +1, >1 score +2); respiration rate (20–30 score +1, >30 score +2); peripheral oxygen saturation (<92% score +2); urea (7–14 mmol/l score +1, >14 mmol/l score +3); CRP (50–100 mmol/l score +1, >100 mmol/l score +2). Glasgow Coma Scale values were not included in risk score calculation, as approximately 90% of patients did not have values available.

2.6. Statistical methods

Continuous data were summarised as median (interquartile range) and categorical as frequency (percentage). Cohorts were compared using Chi-squared or Kruskal-Wallis tests, respectively. Associations between cohorts and outcomes were investigated using logistic regression adjusted for the first risk score. P-values were adjusted for multiple testing using Holm–Bonferroni method. Multivariable analysis of differences between cohorts upon presentation was performed using machine learning models including tree-based models and regularised regression models, combined with bootstrapping and recursive feature elimination. Given the study’s real-world nature, there were a number of missing data points. As this paper is mainly descriptive, we have not performed any imputation for missing data but describe the data as they stand. For each model, the number of patients may vary due to missing values.

3. Results

3.1. Patient characteristics

To compare the clinical characteristics and outcomes of COVID-19 patients in each wave, we collected data for patients admitted to a NHS teaching hospital. 1763 patients were included in this analysis, 680

![Prevalence of "Kent" variant vs other variants, community cases, SE UK](image.png)
in Cohort 1, 213 in Cohort 2 and 870 in Cohort 3. After adjusting for multiple testing, there were no significant differences in age or sex between cohorts (Table 2). Pre-existing neurological disease was more common in cohort 1 (217/680, 31.9%) vs cohorts 2 (44/213, 20.7%) and 3 (218/870, 25.1%), adjusted p-value = 0.017. However, no significant differences in other comorbidities at presentation were seen, including in cardiovascular disease, obesity, COPD or diabetes (Table 2). Similarly, median (IQR) risk scores upon presentation were not significantly different, cohort 1 (10 [6,12] vs cohort 2 (9 [5,11] vs cohort 3 (9 [6,11]), (p = 0.144).

### 3.2. Biochemical characteristics

Biochemical parameters were compared between cohorts using first available measurements following positive SARS-CoV-2 test. Median (IQR) CRP was higher cohort 1 (91 [34, 153.5]) vs cohort 2 (68 [21, 113]) and cohort 3 (72 [23, 131]) (p = 0.002), differences in ferritin, glucose and haemoglobin were also seen. However, no differences were seen for other biochemical parameters, including total white blood cells, lymphocytes, neutrophils, eosinophils, η-dimer, or creatinine (Table 3).

Due to cohort 3 including patients infected with both the original and VOC202012/01 variant (Fig. 1), we further evaluated the distribution of each biochemical parameter according to month of first positive test to look for a bimodal distribution of values (potentially suggestive of strain-related differences). There was a bimodal distribution in CRP values. However, this was seen in both cohorts 1 and 3, suggesting it may be unrelated to strain differences (data not shown). Similarly, using multivariable analysis and various machine-learning methods to classify patients into cohorts based on demographic and biochemical parameters upon presentation, prediction of an individual’s cohort had no greater accuracy than 60%, suggesting no consistent differences in these features between cohorts (data not shown).

### 3.3. Intervention use and outcomes between cohorts

We next looked at differences in treatments and outcomes between the cohorts. Dexamethasone treatment was more common in cohorts 2 and 3 (n = 91, 42.7% and n = 449, 51.6%, respectively) vs cohort 1 (n = 17, 2.5%); similarly, tocilizumab treatment increased between cohorts from 2 patients in cohort 1 (0.2%), to 6 patients in cohort 2 (2.8%) and 42 patients (4.8%) in cohort 3 (Table 4). Remdesivir use was more common in cohort 2 (28, 13.1%) vs cohort 1 (10, 1.5%), but lower in cohort 3 (41, 4.7%) (p < 0.001). Macrolide use decreased with later presentation, with 216 (31.8%), 23 (10.8%) and 66 (7.6%) receiving macrolide therapy in cohorts 1, 2 and 3, respectively. Tetracycline use increased from cohort 1 (63, 9.3%) to cohort 2 (56, 26.3%) and 3 (280, 32.2%) (p < 0.001).

Respiratory support (including any supplemental oxygen through to invasive ventilation during 28 days after first positive test) was lower overall in cohort 2 (106, 49.8%) vs cohorts 1 (438, 64.4%) and 3 (551, 63.3%) (p = 0.006 (Table 4)). Specifically, lower levels of invasive ventilation were seen in cohort 2 (14, 8%) vs cohort 1 (62, 11%) and cohort 3 (108, 14%) (Table S1). However, high-flow nasal oxygen use was higher with later presentation, with 52 (9%), 33 (19%) and 184 (25%) receiving high-flow nasal oxygen, cohort 1 vs cohort 2 vs cohort 3, respectively. ITU admissions were similar between cohort 1 (86, 12.6%), 2 (25, 11.7%) and 3 (146, 16.8%) (p = 0.432) (Table 4).

The 28-day mortality was substantially lower in cohort 2 vs cohort 1 (14% vs 27%, respectively) but was greater in cohort 3 vs cohort 2 (20% vs 14%, respectively) (p < 0.001) (Table 4). Across all cohorts, 28-day mortality increased with risk score. However, mortality rates in cohort 2 for specific risk scores were lower vs cohorts 1 and 3 (Fig. 2A). Moreover, after adjusting for risk score at positive test using a multivariable logistic regression model, odds of death were lower in cohort 2 vs cohort 1 (OR: 0.47; 95% CI: 0.27, 0.79; p = 0.006) but not in cohort 3 (OR: 0.86; 95% CI: 0.64, 1.15; p = 0.308; Fig. 2A).

Respiratory support included treatment with any type of oxygen therapy including supplemental oxygen by nasal canula or facemask, non-invasive ventilation, invasive Ventilation and Optiflow / High-Flow.

### 4. Discussion

The REACT COVID-19 observational database is unique in data granularity and description of routine clinical management [12]. We investigated changes in 28-day mortality associated with the widespread use of dexamethasone and emergence of VOC202012/01. We report lower mortality in cohort 2 (post-dexamethasone, pre VOC202012/01) vs cohort 1 after linear regression and adjustment for risk [14], supporting the RECOVERY dexamethasone arm results [4]. The mortality rate in cohort 3 during VOC202012/01 emergence, however, was increased vs cohort 2, and risk-adjusted odds of death were no different cohort 3 vs cohort 1. This reflects UK wide data and highlights the need for continued evaluation of treatment outcomes with emergence of new SARS-CoV-2 variants [8, 10, 11].

Apart from the increase in dexamethasone treatment, other

---

**Table 2**

|          | Cohort 1 (n = 680) | Cohort 2 (n = 213) | Cohort 3 (n = 1036) | Overall (N = 1763) | P-value (adjusted) |
|----------|-------------------|--------------------|---------------------|-------------------|-------------------|
| Age, median (IQR) | 72 (54.83) | 68 (46.81) | 69 (54.81) | 70 (53.82) | 0.210 |
| Male, n (%) | 387 (56.9%) | 116 (54.5%) | 449 (51.6%) | 952 (54.0%) | 1 |
| Number comorbidities, median (IQR) | 2 (1, 3) | 1 (0, 2) | 1 (1, 3) | 1 (1, 3) | 1 |
| Cardiac disease, n (%) | 215 (31.6%) | 61 (28.6%) | 268 (30.8%) | 544 (30.9%) | 1 |
| COPD, n (%) | 129 (19.0%) | 33 (15.5%) | 143 (16.4%) | 305 (17.3%) | 1 |
| Diabetes, n (%) | 190 (27.9%) | 49 (23.0%) | 227 (26.1%) | 466 (26.4%) | 1 |
| Dementia, n (%) | 31 (4.6%) | 9 (4.2%) | 33 (3.8%) | 73 (4.1%) | 1 |
| Human Immunodeficiency Virus (HIV), n (%) | 4 (0.6%) | 0 (0.0%) | 4 (0.5%) | 8 (0.5%) | 1 |
| Cancer, n (%) | 38 (5.6%) | 11 (5.2%) | 35 (4.0%) | 84 (4.8%) | 1 |
| Neurological disease, n (%) | 217 (31.9%) | 44 (20.7%) | 218 (25.1%) | 479 (27.2%) | 0.017 |
| Obesity, n (%) | 191 (28.1%) | 62 (29.1%) | 301 (34.6%) | 554 (31.4%) | 0.238 |
| Renal disease, n (%) | 204 (30.0%) | 56 (26.3%) | 269 (30.9%) | 520 (30.0%) | 1 |
| Thromboembolism, n (%) | 4 (0.6%) | 0 (0.0%) | 1 (0.1%) | 5 (0.3%) | 1 |
| Risk scores* | Missing, n (%) | 148 (22%) | 52 (24%) | 150 (17%) | 350 (20%) |
| First score, median (IQR) | 10 (6, 12) | 9 (5, 11) | 9 (6, 11) | 9 (6, 11) | 0.144 |

* Based on first available values within 1 day after admission; Statistical significance tested using Kruskal-Wallis for continuous data and Chi-squared for categorical data, p-values adjusted using Bonferroni-Holm correction. Significant values (p < 0.05) indicated in bold.

* Patients defined as having a neurological disease included those recorded as having a diagnosis of epilepsy, a demyelinating condition (e.g. multiple sclerosis), an extra-pyramidal condition (e.g. Parkinson’s disease), stroke, myasthenia gravis, Huntington’s, spina bifida, motor neuron disease, cerebral palsy, a degenerative disease of the nervous system, spinal muscular atrophy, hydrocephalus, alcohol related neurological disease, vascular related neurological disease or Alzheimer’s.
prescribing differences were also evident between cohorts and reflective of increased understanding and emergence of new treatments. Remdesivir was one of the first treatments to demonstrate survival benefit, and to be employed routinely in clinical practice [15, 16]. However, with emergence of dexamethasone and tocilizumab and conflicting evidence around its efficacy, remdesivir use fell [15,16,17]. The difference in tetracycline and macrolide use is also noteworthy and reflects the local antibiotic policy, since macrolide treatment excluded participation in some arms of RECOVERY and ACCORD [3, 4]. Supportive care changed over the course of the first wave, with a shift towards greater use of non-invasive ventilation [18].

Recent reports have suggested that VOC202012/01 is associated with higher mortality, consistent with our finding that 28-day mortality rate was higher in cohort 3 vs cohort 2 [10]. Despite higher use of dexamethasone and other effective therapies in cohort 3, risk-adjusted rate was higher in cohort 3 vs cohort 2 [10]. Despite higher use of dexamethasone and other effective therapies in cohort 3, risk-adjusted rate was higher in cohort 3 vs cohort 2 [10]. Despite higher use of dexamethasone and other effective therapies in cohort 3, risk-adjusted rate was higher in cohort 3 vs cohort 2 [10]. Despite higher use of dexamethasone and other effective therapies in cohort 3, risk-adjusted rate was higher in cohort 3 vs cohort 2 [10]. Despite higher use of dexamethasone and other effective therapies in cohort 3, risk-adjusted rate was higher in cohort 3 vs cohort 2 [10]. Despite higher use of dexamethasone and other effective therapies in cohort 3, risk-adjusted rate was higher in cohort 3 vs cohort 2 [10].
support the hypothesis that VOC202012/01 is associated with higher mortality than the original variant. The increase in high flow-nasal oxygen in later cohorts reflects what has been seen clinically, with various studies demonstrating its benefit in reducing ICU length of stay in specific patients [19, 20]. Whilst dexamethasone has demonstrated efficacy in pre-B1.1.7 SARS-CoV-2 infection, its impact on VOC202012/01 had not been investigated in clinical studies.

It is important to note that, whilst we did see different levels of neurological disease between cohorts, this is unlikely to explain overall mortality rate variation. There were no statistically significant differences in rates of other comorbidities, age or sex, nor consistent variation in other patient characteristics or biochemical parameters at presentation that could explain the observed difference in mortality. Risk scores at presentation did not differ significantly between cohorts. Whilst several statistically significant differences in biochemical parameters between cohorts were reported (including CRP), the absolute differences were small, overall unlikely to be clinically significant, and did not reveal consistent differences between cohort 3 and cohorts 1 and 2 that could be suggestive of differing pathobiology caused by the varying lineages of SARS-CoV-2.

The data capture alongside clinical care is both a strength and limitation to the REACT COVID-19 Study. Whilst this design is more reflective of real-world clinical care, there is greater risk of bias, with sicker patients undergoing more sampling than those demonstrating improvements. The observational design allows only associations rather than causations to be determined, and other possible explanations for differences in mortality but not biochemical parameters must be considered.

It is noteworthy that cohort 2 required lower respiratory support levels and lower levels of invasive ventilation. Whilst our risk score adjusts for oxygen saturation and respiration rate at presentation, the lower requirement for respiratory support in cohort 2 suggests potential differences in disease severity between cohorts that are not fully accounted for by risk scores. Second, our data on strain prevalence are based on PHE local area data rather than direct patient-specific sequencing. Therefore, it was not possible to link outcome directly with lineage data at a patient level [11]. Lineage data are available for greater numbers of patients in wave 3 through national sequencing programmes, but fewer tests were initially sequenced nationally and therefore a comparison was not possible. However, the PHE data reflect what we see in the increasingly available trust lineage data and we intend to investigate specific outcomes related to lineage data in the most recent cohort. Third, the choice of 28-day mortality outcome was made based on national mortality reporting. However, some patients have much longer hospitalisation, particularly those needing ventilation. Therefore, there may be differences in mortality beyond 28 days between cohorts not captured in this analysis that may explain some of the differences described. Fourth, non-patient clinical factors have the potential to influence outcomes including trust COVID-19 pressure and ITU occupancy rates between cohorts. It is also important to bear in mind the initiation of vaccination in the middle of December. Whilst the number of patients vaccinated in the UK by the start of March was not substantial, these could have impacted disease outcomes in cohort 3. Moreover, although we provide an in-depth analysis of COVID-19 outcomes in the UK between June 2020-March 2021, the generalizability of these findings to the rapidly changing COVID-19 landscape around the rest of the world is less. Finally, symptom onset data were not available for all patients and therefore another consideration is the timing of testing relative to symptom onset that may differ between cohorts. However, in our initial analysis of wave 1, which did include symptom

---

**Fig. 2.** (A) 28-day mortality according to first risk score and cohort. Curves represent predicted probability of death within 28 days of first positive test according to cohort based on a binomial logistic regression model fitted to observed data. Shaded areas indicate 95% confidence intervals. (B) Risk-adjusted mortality according to cohort. Odds of death within 28 days of first positive test based on a logistic regression model including first risk score and cohort.

| Variable     | N   | Odds Ratio | p       |
|--------------|-----|------------|---------|
| First risk score | 1413| 1.43 (1.36, 1.51) | <0.001 |
| Cohort       |     |            |         |
| 1            | 532 | Reference  |         |
| 2            | 161 | 0.47 (0.27, 0.79) | 0.006  |
| 3            | 720 | 0.86 (0.64, 1.15) | 0.308  |

---
onset data, there did not appear to be an impact on outcome [13]. With a rapidly changing COVID-19 international picture, future prospective studies are now essential to understand the impact of potential emerging therapeutics [24–29] and changing standard of care, vaccination coverage and variant dynamics, on COVID-19 outcomes and complications such as mucormycosis, as well as how comorbidities impact these [22].

5. Conclusions

The REACT COVID-19 observational study provides a uniquely granular, longitudinal assessment of changes in outcomes in SARS-CoV-2 over the course of this pandemic in a teaching hospital in England. Our data are reflective of larger, cross sectional studies in demonstrating an increase in mortality with the emergence of the VOC202012/01, that appears to cancel out any overall mortality benefit conferred by emerging treatments. The lack of variation in longitudinal clinical parameters suggests that the mechanism of disease remains similar. While it is hoped that widespread vaccination will impact transmission and disease severity of COVID-19 globally, this work highlights the need for ongoing research into treatments to mitigate the impact of future mutations.

Supplementary materials

Supplementary material associated with this article can be found, in the online version, at doi:10.1016/j.jciv.2021.105031.

References

[1] W.J. Guan, W.H. Liang, Y. Hao, H.R. Liang, Z.S. Chen, Y.M. Li, et al., Comorbiditiy and its impact on 1590 patients with COVID-19 in China: a nationwide analysis, Eur. Respir. J. 55 (5) (2020).
[2] W.J Guan, Z-y Ni, Y. Hu, W-h Liang, C-q Ou, J-x He, et al., Clinical Characteristics of Coronavirus Disease 2019 in China, New Engl. J. Med. 382 (18) (2020) 1708–1720.
[3] T. Wilkinson, R. Dixon, C. Page, M. Carroll, G. Griffiths, L-P Ho, et al., ACCORD: a multicentre, seamless, phase 2 adaptive randomisation platform study to assess the efficacy and safety of multiple candidate agents for the treatment of COVID-19 in hospitalised patients: a structured summary of a study protocol for a randomised controlled trial, Trials 21 (1) (2020) 691.
[4] P. Horby, W.S. Lim, J.R. Emmerson, M. Maham, J.L. Bell, L. Limel, et al., Dexamethasone in hospitalised patients with Covid-19, New Engl. J. Med. 384 (8) (2020) 693–704.
[5] P.D. Monk, R.J. Marsden, V.J. Tear, J. Brookes, T.N. Batten, M. Mankowski, et al., Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial, Lancet Respir. Med. 9 (2) (2021) 196–206.
[6] Whiny C. Dexamethasone in the treatment of COVID-19: implementation and management of supply for treatment in hospitals. London: medicines and healthcare products regulatory agency. 2020.
[7] A. Watson, T.M.A. Wilkinson, Respiratory viral infections in the elderly, Ther. Adv. Respir. Dis. 15 (2021) 1753466521990506.
[8] ICNARC. ICNARC report on COVID-19 in critical care: england, Wales and Northern Ireland. 8 January 2021. Available at https://www.icnarc.org/DataArchive/Attachments/download/52086f2–d851–eb11–912d–0050650108b9
(Accessed 6th April 2021).
[9] N.G. Davies, S. Abbott, R.C. Barnard, C.I. Jarvis, A.J. Kucharski, J.D. Munday, et al., Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England, Science 372 (6530) (2021) eabg3055.
[10] M. Patone, K. Thomas, R. Hatch, P.S. Tan, C. Coupland, W. Liao, et al., Analysis of severe outcomes associated with the SARS-CoV-2 Variant of Concern 202012/01 in England using ICNARC Case Mix Programme and QResearch databases, medRxiv (2021), 2021.03.11.21253364.
[11] Office for National Statistics, COVID-19 Infection Survey: estimates of COVID-19 cases to 23 December for England, regions of England and by cases compatible with the new, Available at (2021). https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/adhocs/12716covid19infectionsurveysresultsofcovid2casest02decemberforenglandregionsoffenglandandbycasescompatiblewiththenewvariant (Accessed 6th April).
[12] H. Burke, A. Freeman, A. Dushianthan, M. Celinski, J. Batchelor, H. Phan, et al., Research evaluation alongside clinical treatment in COVID-19 (REACT COVID-19): an observational and biobanking study, BMJ Open 11 (1) (2021), e043012.
[13] H. Burke, A. Freeman, P. O’Regan, O. Wysoksi, A. Freitaz, A. Dushianthan, et al., Novel prognostic biomarkers identified using dynamic time warping analysis in a longitudinal cohort of hospitalised COVID-19, Submitted to BMJ open (2020).
[14] S.R. Knight, A. Ho, R. Pius, I. Buchan, G. Canin, T.M. Drake, et al., Risk stratification of patients admitted to hospital with covid-19 using the ISARIC WHO clinical characterisation protocol: development and validation of the 4C Mortality Score, BMJ 370 (2020) m3339.
[15] A. Fredriksyagh, F. Naina, K. Dharma, M. Mudatur, H. Harapak, Resemdivir and its antiviral activity against COVID-19: a systematic review. Clinic. Epidemiol. Glob. Health 9 (2021) 123–127.
[16] I. Hsu, Covid-19: what now for remdesivir? BMJ 371 (2020) m4457.
[17] P.W. Horby, G. Pessoa-Amorim, L. Petö, C.E. Brightling, R. Sarkar, K. Thomas, et al., Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): preliminary results of a randomised, controlled, open-label, platform trial, medRxiv (2021), 2021.02.11.21429528.
[18] A.A. Sivaloganathan, M. Nasim-Mohi, M.M. Brown, N. Abdul, A. Jackson, S. V. Fletcher, et al., Noninvasive ventilation for COVID-19-associated acute hypoxaemic respiratory failure: experience from a single centre, Br. J. Anaesth. 125 (4) (2020) e368–e71.
[19] R. Mellado-Artigas, B.L. Ferreiro, F. Aigriman, M. Hernández-Sanz, E. Arruti, A. Torres, et al., High-flow nasal oxygen in patients with COVID-19-associated acute respiratory failure, Critical Care 25 (1) (2021) 58.
[20] G.L. Calligaro, U. Lalla, G. Audley, P. Ginn, M.G. Miller, M. Mendelson, et al., The utility of high-flow nasal oxygen for severe COVID-19 pneumonia in a resource-constrained setting; a multi-centre prospective observational study, EClinicalMedicine 28 (2020), 100570.
[21] L. Selarka, S. Sharma, D. Saini, S. Sharma, A. Batra, V.T. Waghmare, et al., Macrormycosis and COVID-19: an epidemic within a pandemic in India, Mycoses 64 (10) (2021) 1253–1260.
[22] A. Watson, L. Oberg, B. Angermann, C.M. Spalluto, M. Hühn, H. Burke, et al., Dysregulation of COVID-19 related gene expression in the COPD lung, Respiratory Research 22 (2021) 164.
[23] H.G. Ough, A. Awasthi, V. Agarwal, R.K. Gaur, G. Dhawan, R. Chandra, A comprehensive review on potential therapeutics interventions for COVID-19. European Journal of Pharmacology 890 (2021) 177341.
[24] F.M.P. van Haren, C. Page, J.G. Laffey, A. Artigas, M. Camps-Rimbas, Q. Nunes, et al., Nebulised heparin as a treatment for COVID-19: scientific rationale and a call for randomised evidence, Critical Care 24 (1) (2020) 454.
[25] A.A. Tree, J.E. Turnbull, K.R. Buttigieg, M.I. Elmore, N. Coombes, J. Hogwood, et al., Fibrinolysed heparin inhibits live wild-type SARS-CoV-2 cell infectivity at therapeutically relevant concentrations, British Journal of Pharmacology 178 (3) (2021) 626–635.
[26] P.D. Monk, R.J. Marsden, V.J. Tear, J. Brookes, T.N. Batten, M. Mankowski, et al., Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial, Lancet Respir. Med. 9 (2) (2021) 196–206.
[27] P.D. Monk, R.J. Marsden, V.J. Tear, J. Brookes, T.N. Batten, M. Mankowski, et al., Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial, The Lancet Respiratory Medicine 9 (2) (2021) 196–206.
[28] A. Watson, C.M. Spalluto, C. McCrae, D. Cellura, H. Burke, D. Cunsoyassi, et al., Dynamics of IFN-γ responses during respiratory viral infection. Insights for therapeutic strategies, American journal of respiratory and critical care medicine 201 (1) (2020) 83–94.
[29] A. Watson, J. Madsen, H. Clark, Dual functioning immune molecules with antiviral and immunomodulatory properties, Frontiers in Immunology 11 (2020) 626598.
[30] H. Burke, A. Freeman, D.C. Cellura, B.L. Stuart, N.J. Brendish, S. Poole, et al., Inflammatory phenotyping predicts clinical outcome in COVID-19, Respiratory research 21 (1) (2020) 1–9.